Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Zevalin and allogeneic transplant for relapsed/refractory aggressive B-cell lymphoma
NCT01434472Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2011
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), sponsored by Fred Hutchinson Cancer Center. Started Nov 2011; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
B-cell non-Hodgkin lymphomadiffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT01434472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01434472.